A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
LY3295668 erbumine had a manageable safety profile as monotherapy and in combination therapy. Although proof-of-concept clinical responses were observed, future studies with biomarker-selected populations and/or novel combinations may yield higher response rates with Aurora kinase A inhibition.
Authors
- Steven G. DuBois (ORCID: https://orcid.org/0000-0003-0882-738X)
- Nadège Corradini (ORCID: https://orcid.org/0000-0002-1942-1222)
- C Karthik
- Isabelle Aerts (ORCID: https://orcid.org/0000-0002-5213-3353)
- Lucas Moreno
- Julie R. Park (ORCID: https://orcid.org/0000-0002-6777-9165)
- Araz Marachelian (ORCID: https://orcid.org/0000-0003-3857-4782)
- Emin Avşar
- Yaël P. Mossé (ORCID: https://orcid.org/0000-0002-3463-0399)
- Roberto Luksch (ORCID: https://orcid.org/0000-0002-7203-4176)
- Brian Weiss (ORCID: https://orcid.org/0000-0001-5154-3134)
- Lisa Howell (ORCID: https://orcid.org/0000-0003-2119-2630)
- Anne L. Ryan (ORCID: https://orcid.org/0000-0002-1979-538X)
- Bram De Wilde (ORCID: https://orcid.org/0000-0003-0213-1322)
- Margaret E. Macy (ORCID: https://orcid.org/0000-0001-6446-9180)
- Matthias Fischer (ORCID: https://orcid.org/0000-0003-1363-1242)
- Jennifer H. Foster (ORCID: https://orcid.org/0000-0002-2126-9768)
- Eunice Yuen (ORCID: https://orcid.org/0000-0003-2145-6368)
- Kieuhoa T. Vo (ORCID: https://orcid.org/0000-0002-9281-7485)
- Suzanne Shusterman (ORCID: https://orcid.org/0000-0002-5988-1792)
- Alba Rubio‐San‐Simón (ORCID: https://orcid.org/0000-0001-6426-7423)
- Chitose Ogawa (ORCID: https://orcid.org/0000-0002-3520-5685)
Institutions
- University of Southern California (US)
- Universitat Autònoma de Barcelona (ES)
- National Health Service (GB)
- St. Jude Children's Research Hospital (US)
- Children's Hospital of Philadelphia (US)
- Children's Hospital of Los Angeles (US)
- Harvard University (US)
- University of California, San Francisco (US)
- University of Cologne (DE)
- Baylor College of Medicine (US)
- Princess Margaret Hospital for Children (AU)
- Ghent University Hospital (BE)
- Riley Hospital for Children (US)
- Alder Hey Children's NHS Foundation Trust (GB)
- Eli Lilly (United Kingdom) (GB)
- Children's Hospital Colorado (US)
- Vall d'Hebron Institut de Recerca (ES)
- Centre Léon Bérard (FR)
- Hospital Infantil Universitario Niño Jesús (ES)
- Eli Lilly (India) (IN)
- Loxo Oncology at Lilly (United States) (US)
- UCSF Benioff Children's Hospital (US)
- Texas Children's Hospital (US)
- University Hospital Cologne (DE)
- Tokyo National Hospital (JP)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- Perth Children's Hospital
- Indiana University School of Medicine
- University of Colorado Anschutz Medical Campus (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
- Institut Curie (FR)
- University of Colorado Denver (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-02-11
- DOI
- https://doi.org/10.1002/cncr.35751
- Citations
- 4
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Eli Lilly and Company